News

Additional New GlycoMark® Test and SGLT-2 Inhibitor Clinical Data To Be Presented at the ADA Advancing Precision Diabetes Medicine Symposium


Posted on October 7, 2019 by


New York, NY (October 7, 2019) — GlycoMark, Inc. announces additional study data describing GlycoMark® test results in patients on SGLT-2 inhibitors are being presented during the American Diabetes Association (ADA) Advancing Precision Diabetes Medicine Research Symposium on October 8 – 9, 2019 in Madrid, Spain.  The GlycoMark test, an FDA-cleared and CE marked blood test used…
Read More

New Clinical Study Data Show the GlycoMark® Test Helps Confirm Compliance and Appropriate Response to SGLT-2 Inhibitors


Posted on June 13, 2019 by


New York, NY (June 13, 2019)— GlycoMark, Inc. announced a new study “GlycoMark 1,5-Anhydroglucitol Values in Patients Taking SGLT-2 Inhibitors” presented at the American Diabetes Association (ADA) Scientific Sessions 2019 involving the GlycoMark test being used for patients with Type 2 diabetes that are being treated with an SGLT-2 inhibitor. SGLT-2 inhibitors are used to…
Read More

New Data on the GlycoMark® Test In Patients Taking SGLT-2 Inhibitors To Be Presented at the American Diabetes Association 79th Scientific Sessions


Posted on June 4, 2019 by


New York, NY (June 4, 2019) — GlycoMark, Inc. announces new data on the GlycoMark® test in patients on SGLT-2 inhibitors are being presented June 8 – 10 at the American Diabetes Association (ADA) Scientific Sessions 2019 in San Francisco.  The GlycoMark test, an FDA-cleared and CE-marked blood test used to monitor glycemic control in patients…
Read More

LabFinder.com Increases Diabetes Awareness with Addition of the GlycoMark® Test


Posted on November 18, 2018 by


New York, NY (November 19, 2018)– LabFinder.com, a convenient online platform for patients to schedule their laboratory and radiology tests and access test results, has announced the addition of the GlycoMark® test to its growing subscriber network. The GlycoMark test is an FDA-cleared blood test for detecting recent hyperglycemia and hyperglycemic excursions in patients with…
Read More

GlycoMark®, Inc. Announces Agreement with PrismHealthDx, Inc. to Expand Diabetes Test Panel with the GlycoMark Test


Posted on November 7, 2018 by


New York, NY (November 7, 2018)— GlycoMark, Inc. and PrismHealthDx, Inc. (PHDx) have announced an agreement to offer the GlycoMark® test to clinicians managing patients with diabetes.  The GlycoMark test is the only FDA-cleared blood test for patients with diabetes that is specific to detecting recent hyperglycemia and hyperglycemic excursions (occurring while fasting, postprandial, or…
Read More

GlycoMark®, Inc. to Launch Live Educational Support via GlycoMark.com for Healthcare Professionals during National Diabetes Month


Posted on November 5, 2018 by


New York, NY (November 5, 2018)—GlycoMark, Inc., the exclusive provider of the GlycoMark® test, is launching live educational support for healthcare professionals through its website, http://www.glycomark.com/, as part of National Diabetes Month.  The new complimentary educational support will offer a live chat and video option via the website in November from 9 a.m. – 5…
Read More

Visit GlycoMark at the NJ AACE for complementary GlycoMark testing!


Posted on September 28, 2018 by


Join us while exhibits are open on October 6 to have your blood drawn by Accu Reference Medical Lab, a preferred GlycoMark lab partner and proud sponsor of conference attendee testing. The GlycoMark test is the only FDA-cleared blood test specific to detecting recent hyperglycemia and hyperglycemic excursions (occurring in the fasting state, postprandial, or both).…
Read More

GlycoMark®, Inc. Announces Partnership with Premier Medical Laboratory Services to Expand Diabetes Test Menu


Posted on September 25, 2018 by


New York, NY.  Sept. 25th, 2018 – GlycoMark®, Inc. has announced a partnership with Premier Medical Laboratory Services (PMLS) to increase the availability of the GlycoMark test, the only FDA-cleared blood test specific to detecting recent hyperglycemia and hyperglycemic excursions in patients with diabetes. With the partnership, PMLS will promote and offer the GlycoMark test…
Read More

Visit GlycoMark at the Cardiometabolic Risk Summit


Posted on September 11, 2018 by


Visit GlycoMark’s booth the Cardiometabolic Risk Summit in San Antonio, TX on September 14-15, 2018, to learn more about the GlycoMark test. This test is the only FDA-cleared blood test specific to detecting recent hyperglycemia and hyperglycemic excursions (occurring in the fasting state, postprandial, or both).  To schedule a meeting with one of our experts,…
Read More

Visit GlycoMark’s Booth at AADE 2018


Posted on July 6, 2018 by


Visit booth #748 at AADE18 organized by the American Association of Diabetes Educators in Baltimore, MD on August 17-20, 2018, to learn more about the GlycoMark test. This test is the only FDA-cleared blood test specific to detecting recent hyperglycemia and hyperglycemic excursions (occurring in the fasting state, postprandial, or both).  To schedule a meeting…
Read More